biosimilar – Health

FDA Approves Herzuma (trastuzumab-pkrb), a Biosimilar to Herceptin

FDA Approves Herzuma (trastuzumab-pkrb), a Biosimilar to Herceptin Print this page INCHEON, South Korea & JERUSALEM–(BUSINESS WIRE) December 14, 2018 –Celltrion, Inc. and Teva Pharmaceutical Industries Ltd. today announced that the U.S. Food and Drug Administration (FDA) has approved Herzuma (trastuzumab-pkrb), a HER2/neu receptor antagonist biosimilar to Herceptin®1 (trastuzumab) for the following indications: Adjuvant Breast… Read More »

Coherus reveals biosimilar launch tactics in battle against Amgen’s Neulasta

Coherus dialed up pressure on Amgen with a recent FDA approval for a Neulasta biosimilar, and now the company has unveiled its bid for a market share steal, using a discounted price and patient and reimbursement services. Udenyca will carry a list price of $ 4,175, a 33% discount to Amgen’s key drug, executives said… Read More »